227 related articles for article (PubMed ID: 23300029)
21. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.
Park K; Lee JL; Park I; Park S; Ahn Y; Ahn JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Med Oncol; 2012 Dec; 29(5):3291-7. PubMed ID: 22460837
[TBL] [Abstract][Full Text] [Related]
23. No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
Miyazaki A; Miyake H; Harada K; Fujisawa M
Anticancer Res; 2015 May; 35(5):3067-73. PubMed ID: 25964597
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.
Ishihara H; Takagi T; Kondo T; Tachibana H; Yoshida K; Omae K; Iizuka J; Kobayashi H; Tanabe K
Int J Clin Oncol; 2018 Jun; 23(3):559-567. PubMed ID: 29327159
[TBL] [Abstract][Full Text] [Related]
25. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
[TBL] [Abstract][Full Text] [Related]
26. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
28. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK; Halabi S; Sanford BL; Hahn O; Michaelson MD; Walsh MK; Feldman DR; Olencki T; Picus J; Small EJ; Dakhil S; George DJ; Morris MJ
J Clin Oncol; 2017 Feb; 35(6):591-597. PubMed ID: 28199818
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.
Iacovelli R; Cartenì G; Sternberg CN; Milella M; Santoni M; Di Lorenzo G; Ortega C; Sabbatini R; Ricotta R; Messina C; Lorusso V; Atzori F; De Vincenzo F; Sacco C; Boccardo F; Valduga F; Massari F; Baldazzi V; Cinieri S; Mosca A; Ruggeri EM; Berruti A; Cerbone L; Procopio G
Eur J Cancer; 2013 Jun; 49(9):2134-42. PubMed ID: 23518211
[TBL] [Abstract][Full Text] [Related]
30. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
[TBL] [Abstract][Full Text] [Related]
31. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
33. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.
Schutz FA; Xie W; Donskov F; Sircar M; McDermott DF; Rini BI; Agarwal N; Pal SK; Srinivas S; Kollmannsberger C; North SA; Wood LA; Vaishampayan U; Tan MH; Mackenzie MJ; Lee JL; Rha SY; Yuasa T; Heng DY; Choueiri TK
Eur Urol; 2014 Apr; 65(4):723-30. PubMed ID: 24184025
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.
Vickers MM; Choueiri TK; Rogers M; Percy A; Finch D; Zama I; Cheng T; North S; Knox JJ; Kollmannsberger C; McDermott DF; Rini BI; Heng DY
Urology; 2010 Aug; 76(2):430-4. PubMed ID: 20223508
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
Buchler T; Poprach A; Bortlicek Z; Lakomy R; Chloupková R; Vyzula R; Zemanova M; Kopeckova K; Svoboda M; Slaby O; Kiss I; Studentova H; Hornova J; Fiala O; Kopecky J; Finek J; Dusek L; Melichar B;
Clin Genitourin Cancer; 2017 Dec; 15(6):e1047-e1053. PubMed ID: 28720439
[TBL] [Abstract][Full Text] [Related]
36. Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma.
Stenehjem DD; Hahn AW; Gill DM; Albertson D; Gowrishankar B; Merriman J; Agarwal AM; Thodima V; Harrington EB; Au TH; Maughan BL; Houldsworth J; Pal SK; Agarwal N
PLoS One; 2019; 14(1):e0210415. PubMed ID: 30682039
[TBL] [Abstract][Full Text] [Related]
37. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.
Sadeghi S; Albiges L; Wood LS; Black SL; Gilligan TD; Dreicer R; Garcia JA; Escudier BJ; Rini BI
Cancer; 2012 Jul; 118(13):3277-82. PubMed ID: 22139966
[TBL] [Abstract][Full Text] [Related]
38. Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.
Elaidi R; Harbaoui A; Beuselinck B; Eymard JC; Bamias A; De Guillebon E; Porta C; Vano Y; Linassier C; Debruyne PR; Gross-Goupil M; Ravaud A; Aitelhaj M; Marret G; Oudard S
Ann Oncol; 2015 Feb; 26(2):378-85. PubMed ID: 25467013
[TBL] [Abstract][Full Text] [Related]
39. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
Grünwald V; Seidel C; Fenner M; Ganser A; Busch J; Weikert S
Br J Cancer; 2011 Nov; 105(11):1635-9. PubMed ID: 22033275
[TBL] [Abstract][Full Text] [Related]
40. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
